MedPath

NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Natural History Protocol for Movement Disorders

Recruiting
Conditions
Parkinson's Disease
Movement Disorder
Tremor
First Posted Date
2022-06-10
Last Posted Date
2025-03-26
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
4000
Registration Number
NCT05413291
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

NIH Investigative Deep Phenotyping Study of Gulf War Veteran Health (Project NIH IN-DEPTH)

Recruiting
Conditions
Gulf War Illness
First Posted Date
2022-05-17
Last Posted Date
2025-03-24
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
85
Registration Number
NCT05375812
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

Phase 2
Conditions
Systemic Inflammation
Microvascular Thrombosis
Neuroinflammation
Interventions
Drug: IV immunoglobulin
Drug: IV normal saline
First Posted Date
2022-04-28
Last Posted Date
2025-04-01
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
45
Registration Number
NCT05350774
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Investigational Use of Neuromuscular Ultrasound

Recruiting
Conditions
Normal Physiology
Peripheral Neuropathy
Motor Neuron Disorder
Muscular Dystrophy
First Posted Date
2022-02-14
Last Posted Date
2024-12-27
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
150
Registration Number
NCT05237973
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Non-invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Functional Movement Disorders

Phase 2
Recruiting
Conditions
Functional Movement Disorder
Interventions
Device: MagStim
Other: Sham Comparator
First Posted Date
2021-12-13
Last Posted Date
2025-03-24
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
50
Registration Number
NCT05155059
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Data Collection of Standard Care of Patients in the EMG Section

Recruiting
Conditions
Neuropathy
Muscle Disorders
Dysautonomia
First Posted Date
2021-09-13
Last Posted Date
2024-12-20
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
200
Registration Number
NCT05041387
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)

Recruiting
Conditions
Spinal and Bulbar Muscular Atrophy
Kennedys Disease
Motor Neuron Disease
First Posted Date
2021-06-30
Last Posted Date
2025-04-24
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
70
Registration Number
NCT04944940
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Teriflunomide in HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis

Phase 1
Recruiting
Conditions
HAM/TSP
Interventions
First Posted Date
2021-03-16
Last Posted Date
2025-04-10
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
24
Registration Number
NCT04799288
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy

Early Phase 1
Recruiting
Conditions
Progressive Multifocal Leukoencephalopathy
Interventions
First Posted Date
2021-03-04
Last Posted Date
2025-03-24
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
12
Registration Number
NCT04781309
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

Phase 2
Active, not recruiting
Conditions
Multiple Sclerosis
Interventions
Drug: tolebrutinib 60mg
Drug: tolebrutinib 120mg
First Posted Date
2021-02-08
Last Posted Date
2024-08-13
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Target Recruit Count
12
Registration Number
NCT04742400
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath